1.41

0.71% +0.01

After Hours: 1.41

Enlivex Therapeutics Ltd (ENLV)

Overview News Price History Option Chain Discussions Forecast Stock Split

Enlivex Therapeutics Ltd stock is currently priced at $1.41, with a 24-hour trading volume of 44,202. It has seen a +0.71% increased in the last 24 hours and a -4.73% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.41 pivot point. If it approaches the $1.42 resistance level, significant changes may occur.

Previous Close:

$1.40

Open:

$1.4

24h Volume:

44,202

Market Cap:

$26.52M

Revenue:

Net Income/Loss:

$-27.16M

P/E Ratio:

-0.9658

EPS:

-1.46

Net Cash Flow:

$-25.87M

1W Performance:

-6.00%

1M Performance:

-4.73%

6M Performance:

-18.97%

1Y Performance:

-48.72%

1D Range:

$1.39

$1.4448

52W Range:

$1.15

$4.59

Enlivex Therapeutics Ltd Stock (ENLV) Company Profile

Name

Enlivex Therapeutics Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 8 662 3301

Address

14 Einstein Street, Ness Ziona

Employee

Twitter

@EnlivexT

Next Earnings Date

2024-05-06

Latest SEC Filings

ENLV's Discussions on Twitter

Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-21	Reiterated	H.C. Wainwright	Buy

Enlivex Therapeutics Ltd Stock (ENLV) Latest News

Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 0.7% - Defense World

Defense World

Israel's Enlivex reports positive results in COVID-19 drug trial - Yahoo Singapore News

Yahoo Singapore News

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events - Yahoo Finance

Yahoo Finance

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

GlobeNewswire Inc.

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled ... - GlobeNewswire

GlobeNewswire

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Zacks Investment Research

Enlivex Therapeutics Ltd Stock (ENLV) Financials Data

Enlivex Therapeutics Ltd (ENLV) Net Income 2024

ENLV net income (TTM) was -$27.16 million for the quarter ending September 30, 2023, a +5.05% increase year-over-year.

Enlivex Therapeutics Ltd (ENLV) Cash Flow 2024

ENLV recorded a free cash flow (TTM) of -$25.87 million for the quarter ending September 30, 2023, a +19.89% increase year-over-year.

Enlivex Therapeutics Ltd (ENLV) Earnings per Share 2024

ENLV earnings per share (TTM) was -$1.47 for the quarter ending September 30, 2023, a +6.37% growth year-over-year.

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.